FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasimigton,	D.O.	20040

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Landry Robert E					<u>RE</u>	2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [REGN]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify					vner
(Last) 777 OLD	•	rst) (LL RIVER ROA	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 07/20/2020								EVP Finance CFO						
(Street)	TOWN N	Y :	10591		- 4. If .	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv Line) X	Form f	filed by One	e Repo	y (Check Ap orting Perso	n
(City)	(SI	tate) ((Zip)												Form filed by More than One Reporting Person				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)		2. Trans Date (Month/I) E:	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			Securiti Benefici	5. Amount of Securities Beneficially Owned Following		r Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price)	Transaction(s) (Instr. 3 and 4)				(111341. 4)
Common	Stock			07/20	/2020	2020			M ⁽¹⁾		3,500) A \$3		9.66	6 27,473		473 D		
Common Stock 07/20/		/2020	2020		F ⁽¹⁾		2,802	2,802 D \$		5.57	7 24,671		571 D						
Common Stock 07/20			/2020	2020			M ⁽¹⁾		5,000	00 A \$5		5.67	29,671		l D				
Common Stock			07/20)/2020				F ⁽¹⁾		4,611 D		\$65	5.57	25,060			D		
Common Stock			07/21/2020					S ⁽¹⁾		388	D	\$64	17.5	24,672			D		
Common Stock			07/21	7/21/2020				S ⁽¹⁾		3	D	\$6	558	24,669			D		
Common Stock														202			I	By 401(k) Plan	
		Т	able II -								osed of				wned				
1. Title of Derivative Conversion Date Security Or Exercise (Month/Day/Year) if any				5. Number of E			Expiratio	6. Date Exercisable and Expiration Date (Month/Day/Year)			d f is g : Securi nd 4)	8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s, (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisal	ble !	Expiration Date	Title	Amou or Numb of Share	er					
Non- Qualified Stock Option (right to buy)	\$399.66	07/20/2020			M ⁽¹⁾			3,500	(2)	1	12/16/2024	Common Stock	3,50	0	\$0.0	25,000)	D	
Non- Qualified Stock Option (right to buy)	\$555.67	07/20/2020			M ⁽¹⁾			5,000	(2)		12/16/2025	Common Stock	5,00	0	\$0.0	5,000		D	

Explanation of Responses:

- 1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- 2. The stock option award vests in four equal annual installments, commencing one year after the date of grant.

/s/**Robert E. Landry

07/22/2020

** Signature of Reporting Person Da

Signature of Reporting Person

Date

 $\label{lem:Remodel} \textbf{Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.}$

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.